ArticleAmerican journal of cancer research2026
Early host adaptation defined by nutritional and inflammatory dynamics predicts disease progression in solid tumours.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesWhether inflammatory and nutritional parameters shift meaningfully in the first months of systemic treatment - and whether these shifts predict outcomes - has not been adequately addressed. We set out to track these changes from treatment initiation to month 3 in adults with newly diagnosed solid tumors, with progression-free and overall survival as primary endpoints.
methodsThis was a single-center prospective study running from August 2023 through August 2024. Patients aged ≥ 18 with histologically proven solid tumors who were about to start systemic anticancer therapy were consecutively enrolled; 100 completed both assessment points. At each visit - baseline and month 3 - we recorded anthropometric data, performed BIA for body composition, administered the MNA-SF, measured handgrip strength and gait speed, and collected fasting blood samples for biochemical analysis. Wilcoxon signed-rank test, Spearman correlation, ROC curves, and logistic regression were the main analytical tools.
resultsNo sarcopenia was detected at baseline. By month 3, only one patient (1%) had developed it. Body fat percentage dropped significantly (P = 0.019); SMI and muscle mass stayed stable. MNA scores were essentially unchanged. Third-month CRP was the only independent predictor of both progression and survival (cut-off 4.74 mg/L; AUC 0.672; P = 0.008). CRP ≥ 4.74 mg/L conferred a 3.63-fold higher progression risk on multivariate analysis (OR 3.63; 95% CI 1.34-9.85; P = 0.011). Albumin correlated with SMI at month 3 (r = 0.214; P = 0.033).
conclusionsSarcopenia was uncommon this early in the disease course. Inflammation, however, was not. Third-month CRP predicted outcomes independently - even in patients whose nutritional scores and muscle indices remained intact. This dissociation suggests inflammatory activation precedes measurable compositional decline. The positive correlation between albumin and SMI supports albumin's role as both a nutritional and functional marker. Routine CRP and albumin checks during early treatment may prove useful for identifying patients who need closer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.